VIDEO: Home OCT offers precise retinal treatment personalization with AI

NEW YORK — In this presentation from OSN New York Retina, Majda Hadziahmetovic, MD, of Duke University, discusses the growing role of Home OCT and how it offers precise personalization in retinal disease treatment.

According to Hadziahmetovic, AI is used to process daily Home OCT scans and determine the efficacy of long-acting drugs.

“You can see when the peak of the fluid gets in the patient who is on the treatment, which can help you decide when you want to treat that patient,” she said.

As Healio previously reported, in 2024, the FDA granted de novo marketing authorization for the first patient self-operated AI-powered Scanly Home OCT device (Notal Vision).

Published by:

Sources/Disclosures

Collapse

Source:

Hadziahmetovic M. Potential role of Home OCT in 2025. Presented at: OSN New York and OSN New York Retina; Nov. 8-10, 2024; New York.

Disclosures:
Hadziahmetovic reports no relevant financial disclosures.

Read more about

This post was originally published on this site